All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Scorr-Insert

X

Find Urology Clinical Drug Pipeline Developments & Deals

All Data

Filters

refresh

×

FILTER DATA :

Study Phase

Country

News Type

Company

Product Type

refresh

Product Type

Development Status

Urovant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

ASCO 2020

Participation Not Confirmed

Update your events

Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results

Contact the Supplier

Lead Product(s): Vibegron

Therapeutic Area: Urology

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 02, 2020

Details:

The double-blind, placebo-controlled 12-week trial, in patients with OAB, studied vibegron 75 mg once-daily compared to placebo and included an active control.

Urovant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Switzerland

Post An Enquiry

ASCO 2020

Participation Not Confirmed

Update your events

Urovant Sciences Announces Results from URO-902 Phase 1 Trials

Contact the Supplier

Lead Product(s): URO-902

Therapeutic Area: Urology

Highest Development Status: Phase II Product Type: Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 04, 2020

Details:

In the trials, URO-902 was well tolerated and the administration via direct injection procedure demonstrated statistically significant improvement in OAB symptoms.